Get started
Author

Andrew Ohyama Parsonson

Observed names: A. Parsonson, A.O., Parsonson, Andrew O Parsonson, Andrew O. Parsonson, Andrew Parsonson
Observed institutions: Camden and Campbelltown Hospitals, The University of Sydney, Nepean Hospital, Chris O’Brien Lifehouse, Sun Yat-sen University Cancer Center, Macquarie Hospital, Macquarie University
ORCID: 0000-0002-4759-3873
Observed ORCID: 0000-0002-4759-3873
OpenAlex ID: A5075594795
Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic
2021 · Andrew O Parsonson, Peter Grimison, et al. · Journal of Telemedicine and Telecare · 21
57O A phase I/II multicenter, first-in-human study of DB-1311/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors
2024 · Y. Cheng, L. Wu, et al. · Annals of Oncology · 12
PDF
Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study.
2024 · John J. Park, Bo Gao, et al. · Journal of Clinical Oncology · 11
PDF
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC).
2025 · Andrew Ohyama Parsonson, Chintan Gandhi, et al. · Journal of Clinical Oncology · 10
PDF
Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study
2021 · Andrew Ohyama Parsonson, Elizabeth Connolly, et al. · ANZ Journal of Surgery · 7
Telehealth cognitive behaviour therapy for the management of sleep disturbance in women with early breast cancer receiving chemotherapy: a feasibility study
2024 · Emma-Kate Carson, Haryana M. Dhillon, et al. · Supportive Care in Cancer · 6
First-in-human study of DM005, an anti-EGFR/c-MET bispecific antibody-drug conjugate, in patients with advanced solid tumors.
2026 · Jin-Ji Yang, Meili Sun, et al. · Journal of Clinical Oncology · 4
Safety and efficacy of the anti-TROP2 antibody-drug conjugate (ADC) IBI130 in patients (pts) with advanced triple-negative breast cancer (TNBC) and other solid tumors: Results from the phase 1 study.
2025 · Fan Wu, Qian Chu, et al. · Journal of Clinical Oncology · 4
A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors.
2025 · Charlotte Rose Lemech, Warren Lance Joubert, et al. · Journal of Clinical Oncology · 3
1496 JSKN033, an innovative subcutaneous-injected fixed-dose combination (FDC) of biparatopic anti-HER2 antibody drug conjugate (ADC) and PD-L1 inhibitor in advanced solid tumor
2024 · Charlotte Lemech, Joe Wei, et al. · Journal for ImmunoTherapy of Cancer · 3
Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy
2024 · Megan Smith-Uffen, John Park, et al. · The Oncologist · 2
PDF
Abstract A03: Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
2022 · Megan Smith-Uffen, John Park, et al. · Cancer Immunology Research · 2
Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance
2026 · Jia Liu, Max Farrow, et al. · Clinical Cancer Research · 1
First-in-human study of ALK201, a FGFR2b-targeting antibody-drug conjugate (ADC) for patients (pts) with advanced solid tumors.
2026 · Dan-yun Ruan, Qi Dang, et al. · Journal of Clinical Oncology · 1
First-in-human study of BG-C9074 (B7-H4–targeting ADC) in advanced solid tumors: Dose escalation and safety expansion.
2026 · Binghe Xu, Linda R. Mileshkin, et al. · Journal of Clinical Oncology · 1
PDF
DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated mCRPC from a phase 1/2 study: Analyses according to prior treatment with lutetium 177 (177Lu)-PSMA-617.
2026 · Mark N. Stein, Andrew Ohyama Parsonson, et al. · Journal of Clinical Oncology · 1
PDF
1017eTiP A phase II trial of DB-1311/BNT324 (B7H3 ADC) combined with BNT327 (PD-L1 x VEGF-A bsAb) or DB-1305/BNT325 (TROP2 ADC) in advanced/metastatic solid tumors
2025 · Y. Guo, T.S. Gourdin, et al. · Annals of Oncology · 1
Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials
2024 · Andrew O. Parsonson, Sunit Sarkar, et al. · Asia-Pacific Journal of Clinical Oncology · 1
Data from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance
2026 · Jia Liu, Max Farrow, et al.
Supplementary Data 1 from Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance
2026 · Jia Liu, Max Farrow, et al.
Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review
2026 · Samantha Ligertwood, Femi E. Ayeni, et al. · Cancer Chemotherapy and Pharmacology
PDF
Abstract A056: Network-integrated clinical trial navigation with ctDNA profiling improves early-phase trial access: Final results from the PANNA-COTA study
2026 · Jia Liu, Max Farrow, et al. · Clinical Cancer Research
112P Phase I study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced CRC and other GI tumors
2026 · C. Lemech, R-H. Xu, et al. · Annals of Oncology
Sustained use and determinants of telehealth in metropolitan cancer care: A multi-centre retrospective study beyond the COVID-19 pandemic
2026 · Andrew Parsonson, Jiawang Cao, et al. · Journal of Telemedicine and Telecare
PDF
BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).
2026 · Johann S. De Bono, Benjamin Garmezy, et al. · Journal of Clinical Oncology
PDF
Works count: 36
Citation count: 91
H-index: 6
I10-index: 4
Year
Topic
Type